Empagliflozina en el tratamiento de la insuficiencia cardiaca con fracción de eyección reducida

Abstract

Introduction: Introduction: Heart failure (HF), is a clinical entity that affects the heart at the functional or structural level, has great social impact due to increased risk factors or comorbidities and as a result represents a mortality rate of 10% annually. Treatment of HF starts from patient education, implementing measures to improve lifestyle to medication adherence to prevent disease progression. Pharmacological treatment encompasses four pharmacological groups called the Fantastic 4, which are optimal for the management of HF with reduced ejection fraction: neprilysin and angiotensin receptor inhibitors (ARNI), Beta-blockers (BB), sodium-glucose cotransporter type 2 (iSGLT2) inhibitors, and mineralocorticoid receptor antagonists (MRA). Objective: To describe the use of empagliflozin in the treatment of heart failure with reduced ejection fraction through a systematic review of scientific articles, providing information for better treatment. Methodology: Descriptive study based on the systematic review of scientific articles published in high impact platforms with updated information of the last 5 years, such as: PubMed, Scielo, Google Scholar, Elsevier. Conclusion: Current therapies for the treatment of heart failure with reduced ejection fraction have provided benefits, and the use of empagliflozin favors a decrease in the rate of mortality and hospitalizations in those patients with RHFpEF whether or not associated with pre-existing comorbidities such as diabetes.